Oligonucleotide-based Therapies Market, Global Outlook and Forecast 2022-2028

February 2022 | 66 pages | ID: O61787A2D7F3EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Oligonucleotide-based Therapies in Global, including the following market information:

Global Oligonucleotide-based Therapies Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Oligonucleotide-based Therapies market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Antisense Oligonucleotide Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Oligonucleotide-based Therapies include Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch & Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics and Akcea Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Oligonucleotide-based Therapies companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Oligonucleotide-based Therapies Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Oligonucleotide-based Therapies Market Segment Percentages, by Type, 2021 (%)

• Antisense Oligonucleotide
• Aptamer
• Other

Global Oligonucleotide-based Therapies Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Oligonucleotide-based Therapies Market Segment Percentages, by Application, 2021 (%)

• Neuromuscular Diseases
• Hepatic VOD
• Other

Global Oligonucleotide-based Therapies Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Oligonucleotide-based Therapies Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Oligonucleotide-based Therapies revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Oligonucleotide-based Therapies revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Biogen
• Sarepta Therapeutics
• Jazz Pharmaceuticals
• Bausch & Lomb
• Alnylam Pharmaceuticals
• Dynavax Technologies
• Kastle therapeutics
• Akcea Therapeutics

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Oligonucleotide-based Therapies Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Oligonucleotide-based Therapies Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL OLIGONUCLEOTIDE-BASED THERAPIES OVERALL MARKET SIZE

2.1 Global Oligonucleotide-based Therapies Market Size: 2021 VS 2028
2.2 Global Oligonucleotide-based Therapies Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Oligonucleotide-based Therapies Players in Global Market
3.2 Top Global Oligonucleotide-based Therapies Companies Ranked by Revenue
3.3 Global Oligonucleotide-based Therapies Revenue by Companies
3.4 Top 3 and Top 5 Oligonucleotide-based Therapies Companies in Global Market, by Revenue in 2021
3.5 Global Companies Oligonucleotide-based Therapies Product Type
3.6 Tier 1, Tier 2 and Tier 3 Oligonucleotide-based Therapies Players in Global Market
  3.6.1 List of Global Tier 1 Oligonucleotide-based Therapies Companies
  3.6.2 List of Global Tier 2 and Tier 3 Oligonucleotide-based Therapies Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Oligonucleotide-based Therapies Market Size Markets, 2021 & 2028
  4.1.2 Antisense Oligonucleotide
  4.1.3 Aptamer
  4.1.4 Other
4.2 By Type - Global Oligonucleotide-based Therapies Revenue & Forecasts
  4.2.1 By Type - Global Oligonucleotide-based Therapies Revenue, 2017-2022
  4.2.2 By Type - Global Oligonucleotide-based Therapies Revenue, 2023-2028
  4.2.3 By Type - Global Oligonucleotide-based Therapies Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Oligonucleotide-based Therapies Market Size, 2021 & 2028
  5.1.2 Neuromuscular Diseases
  5.1.3 Hepatic VOD
  5.1.4 Other
5.2 By Application - Global Oligonucleotide-based Therapies Revenue & Forecasts
  5.2.1 By Application - Global Oligonucleotide-based Therapies Revenue, 2017-2022
  5.2.2 By Application - Global Oligonucleotide-based Therapies Revenue, 2023-2028
  5.2.3 By Application - Global Oligonucleotide-based Therapies Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Oligonucleotide-based Therapies Market Size, 2021 & 2028
6.2 By Region - Global Oligonucleotide-based Therapies Revenue & Forecasts
  6.2.1 By Region - Global Oligonucleotide-based Therapies Revenue, 2017-2022
  6.2.2 By Region - Global Oligonucleotide-based Therapies Revenue, 2023-2028
  6.2.3 By Region - Global Oligonucleotide-based Therapies Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Oligonucleotide-based Therapies Revenue, 2017-2028
  6.3.2 US Oligonucleotide-based Therapies Market Size, 2017-2028
  6.3.3 Canada Oligonucleotide-based Therapies Market Size, 2017-2028
  6.3.4 Mexico Oligonucleotide-based Therapies Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Oligonucleotide-based Therapies Revenue, 2017-2028
  6.4.2 Germany Oligonucleotide-based Therapies Market Size, 2017-2028
  6.4.3 France Oligonucleotide-based Therapies Market Size, 2017-2028
  6.4.4 U.K. Oligonucleotide-based Therapies Market Size, 2017-2028
  6.4.5 Italy Oligonucleotide-based Therapies Market Size, 2017-2028
  6.4.6 Russia Oligonucleotide-based Therapies Market Size, 2017-2028
  6.4.7 Nordic Countries Oligonucleotide-based Therapies Market Size, 2017-2028
  6.4.8 Benelux Oligonucleotide-based Therapies Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Oligonucleotide-based Therapies Revenue, 2017-2028
  6.5.2 China Oligonucleotide-based Therapies Market Size, 2017-2028
  6.5.3 Japan Oligonucleotide-based Therapies Market Size, 2017-2028
  6.5.4 South Korea Oligonucleotide-based Therapies Market Size, 2017-2028
  6.5.5 Southeast Asia Oligonucleotide-based Therapies Market Size, 2017-2028
  6.5.6 India Oligonucleotide-based Therapies Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Oligonucleotide-based Therapies Revenue, 2017-2028
  6.6.2 Brazil Oligonucleotide-based Therapies Market Size, 2017-2028
  6.6.3 Argentina Oligonucleotide-based Therapies Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Oligonucleotide-based Therapies Revenue, 2017-2028
  6.7.2 Turkey Oligonucleotide-based Therapies Market Size, 2017-2028
  6.7.3 Israel Oligonucleotide-based Therapies Market Size, 2017-2028
  6.7.4 Saudi Arabia Oligonucleotide-based Therapies Market Size, 2017-2028
  6.7.5 UAE Oligonucleotide-based Therapies Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Biogen
  7.1.1 Biogen Corporate Summary
  7.1.2 Biogen Business Overview
  7.1.3 Biogen Oligonucleotide-based Therapies Major Product Offerings
  7.1.4 Biogen Oligonucleotide-based Therapies Revenue in Global Market (2017-2022)
  7.1.5 Biogen Key News
7.2 Sarepta Therapeutics
  7.2.1 Sarepta Therapeutics Corporate Summary
  7.2.2 Sarepta Therapeutics Business Overview
  7.2.3 Sarepta Therapeutics Oligonucleotide-based Therapies Major Product Offerings
  7.2.4 Sarepta Therapeutics Oligonucleotide-based Therapies Revenue in Global Market (2017-2022)
  7.2.5 Sarepta Therapeutics Key News
7.3 Jazz Pharmaceuticals
  7.3.1 Jazz Pharmaceuticals Corporate Summary
  7.3.2 Jazz Pharmaceuticals Business Overview
  7.3.3 Jazz Pharmaceuticals Oligonucleotide-based Therapies Major Product Offerings
  7.3.4 Jazz Pharmaceuticals Oligonucleotide-based Therapies Revenue in Global Market (2017-2022)
  7.3.5 Jazz Pharmaceuticals Key News
7.4 Bausch & Lomb
  7.4.1 Bausch & Lomb Corporate Summary
  7.4.2 Bausch & Lomb Business Overview
  7.4.3 Bausch & Lomb Oligonucleotide-based Therapies Major Product Offerings
  7.4.4 Bausch & Lomb Oligonucleotide-based Therapies Revenue in Global Market (2017-2022)
  7.4.5 Bausch & Lomb Key News
7.5 Alnylam Pharmaceuticals
  7.5.1 Alnylam Pharmaceuticals Corporate Summary
  7.5.2 Alnylam Pharmaceuticals Business Overview
  7.5.3 Alnylam Pharmaceuticals Oligonucleotide-based Therapies Major Product Offerings
  7.5.4 Alnylam Pharmaceuticals Oligonucleotide-based Therapies Revenue in Global Market (2017-2022)
  7.5.5 Alnylam Pharmaceuticals Key News
7.6 Dynavax Technologies
  7.6.1 Dynavax Technologies Corporate Summary
  7.6.2 Dynavax Technologies Business Overview
  7.6.3 Dynavax Technologies Oligonucleotide-based Therapies Major Product Offerings
  7.6.4 Dynavax Technologies Oligonucleotide-based Therapies Revenue in Global Market (2017-2022)
  7.6.5 Dynavax Technologies Key News
7.7 Kastle therapeutics
  7.7.1 Kastle therapeutics Corporate Summary
  7.7.2 Kastle therapeutics Business Overview
  7.7.3 Kastle therapeutics Oligonucleotide-based Therapies Major Product Offerings
  7.7.4 Kastle therapeutics Oligonucleotide-based Therapies Revenue in Global Market (2017-2022)
  7.7.5 Kastle therapeutics Key News
7.8 Akcea Therapeutics
  7.8.1 Akcea Therapeutics Corporate Summary
  7.8.2 Akcea Therapeutics Business Overview
  7.8.3 Akcea Therapeutics Oligonucleotide-based Therapies Major Product Offerings
  7.8.4 Akcea Therapeutics Oligonucleotide-based Therapies Revenue in Global Market (2017-2022)
  7.8.5 Akcea Therapeutics Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Oligonucleotide-based Therapies Market Opportunities & Trends in Global Market
Table 2. Oligonucleotide-based Therapies Market Drivers in Global Market
Table 3. Oligonucleotide-based Therapies Market Restraints in Global Market
Table 4. Key Players of Oligonucleotide-based Therapies in Global Market
Table 5. Top Oligonucleotide-based Therapies Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Oligonucleotide-based Therapies Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Oligonucleotide-based Therapies Revenue Share by Companies, 2017-2022
Table 8. Global Companies Oligonucleotide-based Therapies Product Type
Table 9. List of Global Tier 1 Oligonucleotide-based Therapies Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Oligonucleotide-based Therapies Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Oligonucleotide-based Therapies Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Oligonucleotide-based Therapies Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Oligonucleotide-based Therapies Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Oligonucleotide-based Therapies Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Oligonucleotide-based Therapies Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Oligonucleotide-based Therapies Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Oligonucleotide-based Therapies Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Oligonucleotide-based Therapies Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Oligonucleotide-based Therapies Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Oligonucleotide-based Therapies Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Oligonucleotide-based Therapies Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Oligonucleotide-based Therapies Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Oligonucleotide-based Therapies Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Oligonucleotide-based Therapies Revenue, (US$, Mn), 2023-2028
Table 30. Biogen Corporate Summary
Table 31. Biogen Oligonucleotide-based Therapies Product Offerings
Table 32. Biogen Oligonucleotide-based Therapies Revenue (US$, Mn), (2017-2022)
Table 33. Sarepta Therapeutics Corporate Summary
Table 34. Sarepta Therapeutics Oligonucleotide-based Therapies Product Offerings
Table 35. Sarepta Therapeutics Oligonucleotide-based Therapies Revenue (US$, Mn), (2017-2022)
Table 36. Jazz Pharmaceuticals Corporate Summary
Table 37. Jazz Pharmaceuticals Oligonucleotide-based Therapies Product Offerings
Table 38. Jazz Pharmaceuticals Oligonucleotide-based Therapies Revenue (US$, Mn), (2017-2022)
Table 39. Bausch & Lomb Corporate Summary
Table 40. Bausch & Lomb Oligonucleotide-based Therapies Product Offerings
Table 41. Bausch & Lomb Oligonucleotide-based Therapies Revenue (US$, Mn), (2017-2022)
Table 42. Alnylam Pharmaceuticals Corporate Summary
Table 43. Alnylam Pharmaceuticals Oligonucleotide-based Therapies Product Offerings
Table 44. Alnylam Pharmaceuticals Oligonucleotide-based Therapies Revenue (US$, Mn), (2017-2022)
Table 45. Dynavax Technologies Corporate Summary
Table 46. Dynavax Technologies Oligonucleotide-based Therapies Product Offerings
Table 47. Dynavax Technologies Oligonucleotide-based Therapies Revenue (US$, Mn), (2017-2022)
Table 48. Kastle therapeutics Corporate Summary
Table 49. Kastle therapeutics Oligonucleotide-based Therapies Product Offerings
Table 50. Kastle therapeutics Oligonucleotide-based Therapies Revenue (US$, Mn), (2017-2022)
Table 51. Akcea Therapeutics Corporate Summary
Table 52. Akcea Therapeutics Oligonucleotide-based Therapies Product Offerings
Table 53. Akcea Therapeutics Oligonucleotide-based Therapies Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Oligonucleotide-based Therapies Segment by Type in 2021
Figure 2. Oligonucleotide-based Therapies Segment by Application in 2021
Figure 3. Global Oligonucleotide-based Therapies Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Oligonucleotide-based Therapies Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Oligonucleotide-based Therapies Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Oligonucleotide-based Therapies Revenue in 2021
Figure 8. By Type - Global Oligonucleotide-based Therapies Revenue Market Share, 2017-2028
Figure 9. By Application - Global Oligonucleotide-based Therapies Revenue Market Share, 2017-2028
Figure 10. By Region - Global Oligonucleotide-based Therapies Revenue Market Share, 2017-2028
Figure 11. By Country - North America Oligonucleotide-based Therapies Revenue Market Share, 2017-2028
Figure 12. US Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Oligonucleotide-based Therapies Revenue Market Share, 2017-2028
Figure 16. Germany Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 17. France Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Oligonucleotide-based Therapies Revenue Market Share, 2017-2028
Figure 24. China Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 28. India Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Oligonucleotide-based Therapies Revenue Market Share, 2017-2028
Figure 30. Brazil Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Oligonucleotide-based Therapies Revenue Market Share, 2017-2028
Figure 33. Turkey Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Oligonucleotide-based Therapies Revenue, (US$, Mn), 2017-2028
Figure 37. Biogen Oligonucleotide-based Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Sarepta Therapeutics Oligonucleotide-based Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Jazz Pharmaceuticals Oligonucleotide-based Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Bausch & Lomb Oligonucleotide-based Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Alnylam Pharmaceuticals Oligonucleotide-based Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Dynavax Technologies Oligonucleotide-based Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Kastle therapeutics Oligonucleotide-based Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Akcea Therapeutics Oligonucleotide-based Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)